Amarin Corp Plc (AMRN)

[ziploc_1]

Year 2022 was thought to be the year, in which China might initiate sales of Vascepa on the mainland...That didn't happen...The science supporting Vascepa continues to be solid, but price may be a deterrent...it is time for Eddingpharm to approach the Chinese national Health agency with a plan for a low price for Vascepa in return for a high volume of sales.

This could be followed up with a similar plan for European and ROW countries and an authorized generic for the U.S.

The original deal between Amarin and Eddingpharm for cash payment on approval of Vascepa by China and royalties can be renegotiated to be advantageous for both parties and for Chinese patients.